{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:01:01Z","timestamp":1784617261324,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>\n                    A model\u2010based meta\u2010analysis (MBMA) was conducted to compare the efficacy of bimekizumab with other psoriatic arthritis (PsA) treatment regimens using \u2265\u2009 20%\/50%\/70% improvements in American College of Rheumatology (ACR) criteria (ACR20\/50\/70) for patients with PsA. Forty\u2010nine trials of 16 drugs were identified in the literature, comprising 21,340 patients. Trial\u2010level covariates, including prior biologic use, concomitant methotrexate use, time since diagnosis, trial completion year, and active comparator were considered for exploratory models. The final model was selected using leave\u2010one\u2010out cross\u2010validation (LOO CV) to assess predictive performance based on prespecified criteria. LOO CV was conducted for 15 trials; the final model demonstrated that 91.5% (952\/1,040) of the observed treatment differences, and 96.1% of the observed ACR20\/50\/70 response rates were within the 95% prediction interval (PI). Median ACR50 response rates (95% PI) at week 16 in biologic\u2010na\u00efve patients were predicted to be 44% (40\u201349%) for bimekizumab 160\u2009mg, among the highest of all treatments analyzed. Response rates for secukinumab 150\u2009mg and risankizumab 150\u2009mg were 28% (25\u201332%) and 27% (24\u201331%), respectively. The MBMA was also used to predict the probability of success (PoS) of potential head\u2010to\u2010head trials using ACR50 response as the end point with varying sample sizes: vs. secukinumab 150\u2009mg, the PoS for bimekizumab 160\u2009mg was 62% (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009200) and 90% (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009400). Versus risankizumab 150\u2009mg, the PoS for bimekizumab 160\u2009mg was 68% (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009200) and 94% (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009400). In summary, a predictive MBMA described ACR20\/50\/70 outcomes in PsA, allowing accurate and precise treatment comparisons and robust PoS calculations.\n                  <\/jats:p>","DOI":"10.1002\/cpt.3135","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:40:33Z","timestamp":1702255233000},"page":"1007-1014","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model\u2010Based Meta\u2010Analysis of American College of Rheumatology Response Criteria"],"prefix":"10.1002","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-1374","authenticated-orcid":false,"given":"Alan","family":"Maloney","sequence":"first","affiliation":[{"name":"UCB Pharma  Slough UK"},{"name":"Equation AB  Halmstad Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Dua","sequence":"additional","affiliation":[{"name":"UCB Pharma  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada F.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"UCB Pharma  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224431"},{"key":"e_1_2_11_8_1","first-page":"ii49\u201354","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease P.J.","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.69"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.586827"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13807"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1307"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.242"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.122"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-84858-7_7"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_2_11_17_1","unstructured":"Cosentyx Highlights of Prescribing Information. <https:\/\/www.novartis.com\/us\u2010en\/sites\/novartis_us\/files\/cosentyx.pdf> (2023). Accessed 11 July 2023."},{"key":"e_1_2_11_18_1","unstructured":"Cosentyx Summary of Product Characteristics. <https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cosentyx\u2010epar\u2010product\u2010information_en.pdf> (2023). Accessed 11 July 2023."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac607"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac605"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"}],"updated-by":[{"DOI":"10.1002\/cpt.3346","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000}}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.3135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:18:20Z","timestamp":1771327100000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/cpt.3135"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3135","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"2023-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}